USANA HEALTH SCIENCES INC

Listed Company

USNACIK 0000896264NYSEAcceleratedMedicinal Chemicals & Botanical ProductsUtahFY ends Jan 3

Period

FY 2025

Revenue

$925.26M

Net Income

$10.76M

Total Assets

$742.91M

Equity

$533.10M

Shares Out

18.46M

Op. Cash Flow

$22.35M

USNA$21.86−28.63% · past yearDBEQ Basic

Daily closing prices

Business

USANA Health Sciences develops, manufactures, and distributes nutritional supplements, functional foods, and personal care products through direct selling, direct-to-consumer, and retail channels globally. Core offerings include targeted supplement optimizers, vitamin and mineral essentials, meal-replacement foods, and science-based skincare (Celavive), with acquired brands Hiya (children's health subscriptions) and Rise (protein products). The company operates across multiple geographic markets with a significant presence in Asia, serving Brand Partners and direct consumers through multi-channel distribution.

Summary from 10-K filed 2026-03-16

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Net sales	925	855	921	999	1,186
Cost of sales	201	161	177	194	218
Gross profit	724	693	744	805	969
Brand Partner incentives	336	364	394	—	—
Selling, general and administrative	337	263	257	262	279
Impairment	7	0	0	—	—
Cost realignment	6	0	0	—	—
Total operating expenses	687	627	651	697	798
Earnings from operations	37	66	93	108	170
Interest income	2	11	10	4	3
Interest expense	−842,000	−281,000	−262,000	−192,000	—
Other, net	3	−1	7,000	−3	−2
Other income (expense), net	4	10	9	1	450,000
Earnings before income taxes	42	76	102	109	171
Income taxes	30	34	39	39	54
Net earnings	11	42	64	69	—
Less: Net earnings attributable to redeemable noncontrolling interest	717,000	30,000	0	0	—
Net earnings attributable to USANA	11	42	64	69	117
Basic (in dollars per share)	0.58	2.2	3.31	3.6	5.78
Diluted (in dollars per share)	0.58	2.19	3.3	3.59	5.73
Basic (in shares)	19	19	19	19	20
Diluted (in shares)	19	19	19	19	20
Foreign currency translation adjustment	7	−9	−1	−15	2
Tax benefit (expense) related to foreign currency translation adjustment	−658,000	434,000	390,000	2	2
Other comprehensive income (loss), net of tax	6	−9	−908,000	−13	4
Comprehensive income	18	33	63	56	—
Less: comprehensive income attributable to redeemable noncontrolling interest	717,000	30,000	0	0	—
Comprehensive income attributable to USANA	17	33	63	56	121

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	158	182	330	288	240
Inventories	103	70	61	67	98
Prepaid expenses and other current assets	27	28	26	29	27
Total current assets	288	279	418	384	365
Property and equipment, net	94	95	100	98	102
Goodwill	138	144	17	17	18
Intangible assets, net	133	152	30	32	30
Deferred tax assets	27	20	13	10	5
Other assets	62	59	55	55	58
Total assets	743	748	633	597	578
Accounts payable	17	12	10	11	14
Line of credit	14	23	786,000	0	—
Other current liabilities	97	105	108	133	147
Total current liabilities	129	140	119	144	161
Deferred tax liabilities	5	4	5	4	7
Other long-term liabilities	23	18	12	14	14
Total liabilities	157	162	136	—	—
Redeemable noncontrolling interest	53	54	0	—	—
Common stock, $0.001 par value; Authorized -- 50,000 shares, issued and outstanding 18,281 as of January 3, 2026 and 19,064 as of December 28, 2024	18,000	19,000	19,000	19,000	19,000
Additional paid-in capital	84	76	66	56	50
Retained earnings	466	479	445	392	345
Accumulated other comprehensive income (loss)	−16	−23	−14	−13	458,000
Total stockholders' equity attributable to USANA	533	532	497	434	395
Total liabilities, redeemable noncontrolling interest, and stockholders' equity	743	748	633	597	578

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Depreciation and amortization	33	15	13	13	13
Right-of-use asset reduction	7	8	8	8	9
(Gain) loss on sale of property and equipment	−2	1,000	10,000	141,000	61,000
Equity-based compensation expense	14	15	15	13	14
Deferred income taxes	−7	−7	−3	−7	−3
Inventory write-down	3	2	3	6	4
Inventories	−35	−2	2	16	−15
Prepaid expenses and other assets	621,000	−3	110,000	−3	−2
Accounts payable	5	−1	−428,000	−3	−5
Other liabilities	−14	−7	−30	−9	−11
Net cash provided by (used in) operating activities	22	61	71	104	121
Proceeds from the settlement of net investment hedges	0	1	4	5	0
Payments for net investment hedge	−1	−870,000	−1	0	−2
Proceeds from acquisition working capital adjustment	865,000	0	0	—	—
Payments to acquire businesses, net of cash acquired	0	−203	0	−7	0
Proceeds from sale of property and equipment	4	64,000	15,000	7,000	15,000
Purchases of property and equipment	−14	−10	−14	−10	−13
Net cash provided by (used in) investing activities	−10	−213	−12	−12	−14
Repurchase of common stock	−28	−9	−12	−25	−178
Borrowings on line of credit	18	24	2	11	0
Payments on line of credit	−27	−1	−750,000	−11	0
Payments related to tax withholding for net-share settled equity awards	−2	−3	−3	−5	−4
Distributions to redeemable noncontrolling interest	−2	0	0	—	—
Payments for contingent consideration	0	0	−338,000	0	0
Net cash provided by (used in) financing activities	−41	10	−14	−30	−181
Effect of exchange rate changes on cash, cash equivalents, and restricted cash	5	−6	−3	−14	2
Net increase (decrease) in cash, cash equivalents, and restricted cash	−23	−149	42	48	−72
Interest	663,000	76,000	68,000	49,000	10,000
Right-of-use assets obtained in exchange for lease obligations	9	12	6	6	5
Net working capital adjustment receivable	0	778,000	0	0	—
Accrued purchases of property and equipment	1,000	42,000	117,000	679,000	383,000
Accrued excise tax for repurchase of common stock	231,000	39,000	54,000	0	0

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro

Frequently asked questions

What is USANA HEALTH SCIENCES INC's CIK number?

USANA HEALTH SCIENCES INC's SEC CIK number is 0000896264 (896264). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.

Where can I find USANA HEALTH SCIENCES INC's SEC filings?

All of USANA HEALTH SCIENCES INC's EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.

When did USANA HEALTH SCIENCES INC last report earnings?

USANA HEALTH SCIENCES INC (USNA) most recently filed an earnings 8-K with the SEC on May 5, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0000896264-26-000030). This is USANA HEALTH SCIENCES INC's most recent earnings filing of record — not a forecast of its next earnings date.

What is USANA HEALTH SCIENCES INC's most recent earnings 8-K?

USANA HEALTH SCIENCES INC's latest earnings 8-K (Item 2.02) was filed May 5, 2026 under accession 0000896264-26-000030. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.

View USANA HEALTH SCIENCES INC's latest earnings 8-K →
Look up any company's CIK number →